Sphera Funds Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Sphera Funds Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-24,752	Closed	-$1.26M	–	114
2020 Q1	$1.26M	Buy	+24,752	New	+$1.66M	0.16%	61
2019 Q2	–	Sell	-80,000	Closed	-$4.23M	–	120
2019 Q1	$4.23M	Sell	80,000 -67,000	-46%	-$3.29M	0.39%	60
2018 Q4	$6.03M	Buy	+147,000	New	+$5.51M	0.68%	34
2018 Q1	–	Sell	-100,000	Closed	-$3.94M	–	155
2017 Q4	$3.94M	Sell	100,000 -27,000	-21%	-$1.01M	0.46%	53
2017 Q3	$3.94M	Sell	127,000 -23,000	-15%	-$647K	0.56%	49
2017 Q2	$4.1M	Buy	+150,000	New	+$4.46M	0.7%	42
2017 Q1	–	Sell	-125,000	Closed	-$1.81M	–	129
2016 Q4	$1.81M	Buy	+125,000	New	+$2.2M	0.46%	62

Other funds holding GBT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Sphera Funds Management's GBT Position: Q2 2020 in Review

Sphera Funds Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2020, closing a stake of 24,752 shares — an estimated $1.26M sold.

Sphera Funds Management first reported a position in GBT in Q4 2016 and held it in 7 quarters. The position peaked at $6.03M in Q4 2018. 253 funds tracked by Wall St. Rank hold GBT as of Q2 2020.

Sphera Funds Management reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
Sphera Funds Management sold 24,752 Global Blood Therapeutics, Inc. shares in Q2 2020, an estimated $1.26M.
Sphera Funds Management first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 7 quarters.
Sphera Funds Management's Global Blood Therapeutics, Inc. position peaked at $6.03M in Q4 2018.
253 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2020.

Based on Sphera Funds Management's 13F filing for Q2 2020, filed 13 Aug 2020.